Prostate Cancer Symptoms Tips What is prostate cancer symptoms? We have tips about prostate cancer symptoms

Tambahkan foto profil

Thank you for using rssforward.com! This service has been made possible by all our customers. In order to provide a sustainable, best of the breed RSS to Email experience, we've chosen to keep this as a paid subscription service. If you are satisfied with your free trial, please sign-up today. Subscriptions without a plan would soon be removed. Thank you!

Main Category: Conferences
Article Date: 06 Mar 2013 - 9:00 PST
Life Sciences organisations in Europe are facing unprecedented challenges: a heightened competitive state is squeezing margins, whilst at the same time emerging markets bring new opportunities as well complexities that require water-tight commercial compliance, firm controls on discounts, rebates and incentives as well as highly skilled teams with a clear strategy and good insights.

Bringing your organisation together with others is our objective and the reason why The European Pricing Platform & ModelN are again joining forces to host their 3rd European Annual Pricing & Profit Optimisation Forum, focused entirely on Life Sciences.

This year's conference will again take place over 2 days and the agenda has been built to provide compelling plenary sessions as well as cater for Med-tech and Pharma-Biotech tracks with some of the most influential industry experts and some practical and tangible case studies.

The success of last year's forum was down to 3 factors:

• High caliber of speakers and content
• Industry specific with focus on sub-industries
• Only event of its kind geared towards REAL networking

This is a unique opportunity to discuss, learn and challenge both strategic and tactical topics affecting Life Sciences professionals in Europe, thus providing a holistic perspective for attendees to take back into their organisations.

This forum will allow you to take the pulse of what is happening for strategies, processes and technologies, as well as hear approaches you might not have been aware of. 


This Forum will help build your and your teams' knowledge, providing you the opportunity to discuss how you might apply it in your company to improve performance.

Full program

Practical information:

Date: 5th & 6th June 2013
Venue: Grand Hôtel Suisse-Majestic
Avenue des Alpes 45

1820 Montreux

Switzerland
Rates:
€ 1495,00 for non-EPP Participants

€ 1346,00 for EPP Participants
"Early bird action": Apply before the 30th of March and save € 300,00
Website for information or registration: http://www.pricingplatform.eu
For more information, e-mail: ilse.stevens@pricingplatform.eu

• Additional
• References
• Citations

Thank you for using rssforward.com! This service has been made possible by all our customers. In order to provide a sustainable, best of the breed RSS to Email experience, we've chosen to keep this as a paid subscription service. If you are satisfied with your free trial, please sign-up today. Subscriptions without a plan would soon be removed. Thank you!

Main Category: HIV / AIDS
Also Included In: Liver Disease / Hepatitis
Article Date: 06 Mar 2013 - 9:00 PST
80 percent of patients achieved early treatment success* with faldaprevir^ plus PegIFN/RBV highlighting the potential to reduce treatment duration from 48 to 24 weeks. Interim results indicate potent activity of faldaprevir in HCV/HIV co-infected patients

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).1 These patients have a high unmet medical need due to limited treatment options; up to 10 million people2 are co-infected with HIV and HCV worldwide and it is estimated that only around one-third of those diagnosed actually receive HCV treatment.3

These interim results from STARTVersoTM 4, demonstrate early treatment success in a majority of patients regardless of whether they were treatment-naïve or relapsed after prior treatment for HCV.  Patients who achieved early treatment success may be eligible for 24 weeks rather than the standard 48 weeks of treatment with PegIFN/RBV. Interim on-treatment data show that 84 percent of patients had undetectable levels of HCV at week 12 of treatment with this regimen.1

"Several factors influence the likelihood of treatment success in HCV mono-infected patients, including personal genetic makeup, viral genotype and stage of liver disease. Co-infection with HIV contributes additional factors, including potential drug-drug interactions that influence treatment decisions and outcomes," said lead study Investigator Douglas Dieterich, MD, Professor of Medicine, Liver Diseases at Mount Sinai Medical Center, New York, NY. "The early virologic response data from STARTVersoTM 4 are encouraging, especially given the inclusion of patients with cirrhosis, and we look forward to the final trial outcomes."

A diverse range of patients, including the more challenging to cure, are being treated in this study; 17 percent have liver cirrhosis, an advanced form of liver disease, and 22 percent of patients had relapsed after previous treatment with PegIFN/RBV.

Additional data presented at this meeting examined the drug-drug interactions (DDI) of faldaprevir with commonly-prescribed HIV medications darunavir/ritonavir, efavirenz, and tenofovir. The three Phase I studies demonstrated that there was no clinically relevant effect of faldaprevir on these HIV medications.4

"We are proud to present interim Phase III results from STARTVersoTM 4 in patients co-infected with HCV and HIV; the potential for a shorter treatment duration for these patients is important, particularly in reducing the length of time they are exposed to possible side effects associated with a year-long course of interferon," said Professor Klaus Dugi, Senior Vice President Medicine at Boehringer Ingelheim. "Patients with HCV/HIV co-infection have a high unmet clinical need. The encouraging efficacy results and manageable interactions with HIV medications suggest faldaprevir in combination with PegIFN/RBV could be a viable treatment option for this important patient population."

The most frequent adverse events (AEs) in STARTVersoTM 4 were nausea (37%), fatigue (33%), diarrhoea (27%), headache (23%), and weakness (22%). The safety results of this study were thus comparable to those observed in HCV mono-infected treatment-naïve patients in prior faldaprevir clinical studies.1

Faldaprevir is an oral once-daily protease inhibitor, specifically designed to target and inhibit viral replication in the liver. Interferon-based therapy with faldaprevir is effective in a broad spectrum of genotype-1 patients.  In addition to the results presented today, the ongoing Phase III trial programme, STARTVerso, evaluates faldaprevir combined with PegIFN/RBV in treatment-naïve and treatment-experienced genotype-1 HCV patients.

• Additional
• References
• Citations